**New prognostic index for neoadjuvant chemotherapy outcomes in patients with advanced high-grade serous ovarian cancer**

Chuying Huo1,2,#, Bin Wu1,#, Dongdong Ye1,#, Miaochun Xu3, Shaolin Ma1,2, Aoshuang Cheng1,2, Yunyun Liu1,2, Chunxian Huang1,2, Yuhao Zhang1, Zhongqiu Lin1,2, Xinyuan Lei4,\*, Bowen Li2,5,\*, Huaiwu Lu1,2,\*

1Department of gynecological oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, China.

2Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, China.

3 Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

4 Department of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, 11794

5 Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, China

**Figure S1. The forest maps of** **logistics** **regression analysis: odd ratio (OR) for the response to platinum chemotherapy.**

The forest maps of (A) univariable and (B) multivariable logistics regression analysis with the OR for the response to platinum chemotherapy.

****

**Figure S2. The forest maps of the Cox regression analysis: hazard ratios (HR) for progression-free survival (PFS).**

The forest maps of (A) univariable and (B) multivariable Cox regression analysis with the HR for the PFS.

****

**Figure S3. The forest maps of the Cox regression analysis: hazard ratios (HR) for overall survival (OS).**

The forest maps of (A) univariable and (B) multivariable Cox regression analysis with the HR for the OS.

**Supplementary table 1. Diagnostic sensitivity and specificity in the ROC curve.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **AUC** | **P value** | **Sensitivity** | **Specificity** | **Youden index** | **Cut off\*** |
| CA125 | 0.472 | 0.074 | 0.25 | 0.822 | 0.856 | 2107.5 |
| HE4 | 0.386 | 0.071 | 0.05 | 0.735 | 0.989 | 8198 |
| Neutrophils | 0.656 | 0.065 | 0.75 | 0.681 | 0.622 | 5.77 |
| Monocyte | 0.597 | 0.072 | 0.6 | 0.686 | 0.622 | 0.535 |
| Lymphocyte | 0.479 | 0.068 | 0.75 | 0.259 | 0.333 | 1.045 |
| Platelet | 0.498 | 0.07 | 0.75 | 0.524 | 0.411 | 337.5 |
| Fibrinogen | 0.533 | 0.074 | 0.4 | 0.805 | 0.756 | 4.9 |
| NLR | 0.67 | 0.063 | 0.95 | 0.449 | 0.411 | 3.61 |
| MLR | 0.603 | 0.069 | 0.6 | 0.746 | 0.6 | 0.42 |
| PLR | 0.496 | 0.068 | 0.8 | 0.535 | 0.3 | 227.065 |
| FLR | 0.52 | 0.069 | 0.9 | 0.465 | 0.2 | 2.225 |
| SII | 0.634 | 0.065 | 0.55 | 0.573 | 0.722 | 2083.665 |

NLR = Neutrophil-to-lymphocyte ratio; PLR = Platelet-to-lymphocyte ratio; MLR = Monocyte-to-lymphocyte ratio; FLR = Fibrinogen-to-lymphocyte ratio; SII = Systemic immune-inflammation index.

\*Cutoff value that maximized the sum of sensitivity and specificity in the ROC curve.